Vasileios Giannopapas

Dr. Vasileios Giannopapas

Second Department of Neyrology, National and Kapodistrian University of Athens, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
George S. KorresGeorge S. Korres
George S. Korres
DKDimitrios Kitsos
Dimitrios Kitsos
Diego KaskiDiego Kaski
Diego Kaski
ATAnthi Tsogka
Anthi Tsogka
Sotirios GiannopoulosSotirios Giannopoulos
Sotirios Giannopoulos
KVKonstantinos Ioannis Voumvourakis
Konstantinos Ioannis Voumvourakis
Clinical manifestations of COVID-19 include symptoms of vertigo and dizziness, which is rather unsurprising, since SARS-CoV-2 neurotropism may inflict a broad spectrum of neuropathic effects. The widespread nature of central and peripheral audiovestibular pathways suggests that there may be several probable pathophysiological mechanisms. The cytokine storm, CNS infiltration of the virus through ACE 2 receptors, and other systemic factors can be responsible for the significant number of COVID-19 patients reported to experience symptoms of vertigo and dizziness. In this paper, we present a systematic review of clinical studies reporting the detection of dizziness and vertigo as clinical manifestations of COVID-19 and discuss their etiopathogenesis.

Verified
Journal Article
Open access
PDF file
Vasileios GiannopapasVasileios Giannopapas
Vasileios Giannopapas
LPLina Palaiodimou
Lina Palaiodimou
DKDimitrios Kitsos
Dimitrios Kitsos
GPGeorgia Papagiannopoulou
Georgia Papagiannopoulou
KSKonstantina Stavrogianni
Konstantina Stavrogianni
Sotirios GiannopoulosSotirios Giannopoulos
Sotirios Giannopoulos
Introduction: The interactions between Diabetes Mellitus type II (DMII) and Multiple Sclerosis (MS) lead to higher levels of fatigue, higher risk of physical disability, faster cognitive decline, and in general a lower quality of life and a higher frequency of depression compared to the general population. All of the above accelerate the disability progression of patients with MS, reduce the patients’ functional capacity, and further increase their psychological and economic burden. Methods: This systematic review and meta-analysis aims to calculate the prevalence of DMII in the MS population. Following PRISMA guidelines, a thorough search of the Medline Pubmed, Cochrane Library, and Scopus databases was performed, focusing on the frequency of DMII in the MS population. Results: A total of 19 studies were included in the synthesis. The results of the main meta-analysis of random effects using R studio 3.3.0 for Windows and the Meta r package showed that the prevalence of DMII in the MS population is 5% (95% CI [0.03, 0.07], 19 studies, I2 = 95%, pQ < 0.001). Additional subgroup analysis based on region showed a difference of 4.4% (I2 = 95.2%, pQ < 0.001), psubgroupdifference = 0.003) between European and non-European participants, while demographic- and MS-specific characteristic (EDSS, Disease Duration) did not seem to affect the prevalence of DMII in the MS population (p = 0.30, p = 0.539, p = 0.19, p = 0.838). No publication bias was discovered (Egger’s p test value: 0.896). Conclusions: Even though the prevalence of DMII in the MS population is lower than 10% (the reported prevalence of DMII in the general population) the interactions between the two conditions create significant challenges for MS patients, their caregivers, and physicians. DΜΙΙ should be systematically recorded in the case of MS patients to clearly delineate any potential relationship between the two conditions. Additionally, more structured studies investigating the interactions of MS and DMΙΙ as well as the direction of the causation between those two conditions are necessary in order to gain a deeper insight into the nature of the interaction between MS and DMII.

31 December 2022 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
Vasileios GiannopapasVasileios Giannopapas
Vasileios Giannopapas
DKDimitrios Kitsos
Dimitrios Kitsos
ATAnthi Tsogka
Anthi Tsogka
JTJohn S. Tzartos
John S. Tzartos
GPGeorge Paraskevas
George Paraskevas
DBDaphne Bakalidou
Daphne Bakalidou
Objective: Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of the central nervous system (CNS). The most common clinical manifestations of MS are spasticity, pain, vesico-urethral disorders, cognitive impairments, chronic fatigue and sexual dysfunction. This review aims to explore the possible therapeutic options for managing sexual dysfunction in people with MS (PwMS). Method: A thorough search of the PubMed Medline database was performed. Records were limited to clinical studies published between 01/01/2010 up to 01/01/2022. The results were screened by the authors in pairs. Results: The search identified 36 records. After screening, 9 records met the inclusion–exclusion criteria and were assessed. The pharmacological approaches investigated the effectiveness of sildenafil, tadalafil and onabotulinumtoxinA. Of the interventional studies the non-pharmacological investigated, the effectiveness of aquatic exercises, the application of pelvic floor exercises,the combination of pelvic floor exercises and mindfulness technique, the combination of pelvic floor exercises and electro muscular stimulation with electromyograph biofeedback, the application of yoga techniques and the efficacy of assistive devices like the clitoral vacuum suction device and the vibration device. Conclusion: The management of sexual dysfunction in PwMS needs to be further investigated. A team of healthcare professionals should be involved in the management of SD in order to address not only the primary (MS-related) SD symptoms but the secondary and tertiary as well. The main limitations that were identified in the existing literature were related to MS disease features, sample characteristics and evaluation tools and batteries.

18 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Vasileios GiannopapasVasileios Giannopapas
Vasileios Giannopapas
MSMaria Ioanna Stefanou
Maria Ioanna Stefanou
VSVassiliki Smyrni
Vassiliki Smyrni
DKDimitrios Kitsos
Dimitrios Kitsos
MKMaria Kosmidou
Maria Kosmidou
Sotirios GiannopoulosSotirios Giannopoulos
Sotirios Giannopoulos
Background: While obesity has been shown to elevate the risk of developing multiple sclerosis (MS), there is a lack of strong evidence regarding its role in the disability progression and status of MS patients. Methods: This systematic review and meta-analysis aimed to provide comparative estimates of WC and BMI in patients with MS (PwMS) and to investigate potential associations between the waist circumference (WC) and body mass index (BMI) and demographic and specific MS characteristics. Adhering to PRISMA guidelines, a detailed search of the MEDLINE PubMed, Cochrane Library, and Scopus databases was conducted. Results: A total of 16 studies were included. The pooled mean WC and BMI among PwMS was estimated to be 87.27 cm (95%CI [84.07; 90.47]) and 25.73 (95%CI [25.15; 26.31]), respectively. Meta-regression models established a significant bidirectional relationship between WC and the Expanded Disability Scale (EDSS) (p < 0.001) but not between BMI and EDSS (p = 0.45). Sensitivity analyses showed no association between WC and age (p = 0.48) and a tendency between WC and disease duration (p = 0.08). Conclusions: Although WC measurements classify PwMS as normal weight, BMI measurements classify them as overweight. Therefore, WC should complement BMI evaluations in clinical practice. Additionally, our findings highlight the significant association between abdominal fat, as indicated by WC, and disease progression. Considering the heightened risk of cardiovascular comorbidity and mortality among PwMS, we recommend integrating both WC and BMI as standard anthropometric measurements in routine clinical examinations and targeted prevention strategies for PwMS.

11 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ATAnthi Tsogka
Anthi Tsogka
DKDimitrios Kitsos
Dimitrios Kitsos
KSKonstantina Stavrogianni
Konstantina Stavrogianni
Vasileios GiannopapasVasileios Giannopapas
Vasileios Giannopapas
ACAthanasios K. Chasiotis
Athanasios K. Chasiotis
Sotirios GiannopoulosSotirios Giannopoulos
Sotirios Giannopoulos
This review attempted to explore all recent clinical studies that have investigated the clinical and autoimmune impact of gut microbiota interventions in multiple sclerosis (MS), including dietary protocols, probiotics, fecal microbiota transplantation (FMT), and intermittent fasting (IF). Methods: Thirteen studies were held between 2011 and 2023 this demonstrated interventions in gut microbiome among patients with MS and their impact the clinical parameters of the disease. These included specialized dietary interventions, the supply of probiotic mixtures, FMT, and IF. Results: Dietary interventions positively affected various aspects of MS, including relapse rates, EDSS disability scores, MS-related fatigue, and metabolic features. Probiotic mixtures showed promising results on MS-related fatigue, EDSS parameters, inflammation; meanwhile, FMT—though a limited number of studies was included—indicated some clinical improvement in similar variables. IF showed reductions in EDSS scores and significant improvement in patients’ emotional statuses. Conclusions: In dietary protocols, clinical MS parameters, including relapse rate, EDSS, MFIS, FSS, and MSQoL54 scales, were significantly improved through the application of a specific diet each time. Probiotic nutritional mixtures promote a shift in inflammation towards an anti-inflammatory cytokine profile in patients with MS. The administration of such mixtures affected disability, mood levels, and quality of life among patients with MS. FMT protocols possibly demonstrate a therapeutic effect in some case reports. IF protocols were found to ameliorate EDSS and FAMS scores. All interventional means of gut microbiome modulation provided significant conclusions on several clinical aspects of MS and highlight the complexity in the relationship between MS and the gut microbiome.

26 November 2024 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
EMEffimia G. Marcellou
Effimia G. Marcellou
SSSophia Stasi
Sophia Stasi
Vasileios GiannopapasVasileios Giannopapas
Vasileios Giannopapas
KBKari Bø
Kari Bø
DBDaphne Bakalidou
Daphne Bakalidou
GPGeorge Papathanasiou
George Papathanasiou